Kurv Yield Premium Strategy Tesla (TSLA) ETF(TSLP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

TSLP Kurv Yield Premium Strategy Tesla (TSLA) ETF

Market Closed 09-20 16:00:00 EDT

23.82

-0.16

-0.66%

盘后23.82

+0.000.00%

17:37 EDT

High23.92	Low23.76	Vol9.21K
Open23.92	D1 Closing23.98	Amplitude0.65%
Mkt Cap4.53M	Tradable Cap4.53M	Total Shares190.00K
T/O219.52K	T/O Rate4.85%	Tradable Shares190.00K
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"TSLP","market":"US","secType":"STK","nameCN":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","latestPrice":23.8199,"timestamp":1726862400000,"preClose":23.9775,"halted":0,"volume":9212,"hourTrading":{"tag":"盘后","latestPrice":23.8199,"preClose":23.8199,"latestTime":"17:37 EDT","volume":3,"amount":73.74,"timestamp":1726868239539},"delay":0,"floatShares":190000,"shares":190000,"eps":0,"marketStatus":"Market Closed","change":-0.1576,"latestTime":"09-20 16:00:00 EDT","open":23.916,"high":23.916,"low":23.7596,"amount":219519.038,"amplitude":0.006523,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1727078400000},"marketStatusCode":7,"adr":0,"exchange":"AMEX","adjPreClose":23.9775,"sharesOutstanding":190000,"nav":23.98,"aum":4556200,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":23.8199,"preClose":23.8199,"latestTime":"17:37 EDT","volume":3,"amount":73.74,"timestamp":1726868239539},"volumeRatio":0.8376520785170272,"impliedVol":0.0196,"impliedVolPercentile":0.0325},"requestUrl":"/m/hq/s/TSLP","defaultTab":"news","newsList":[{"id":"2463140495","title":"Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097","url":"https://stock-news.laohu8.com/highlight/detail?id=2463140495","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463140495?lang=en_us&edition=fundamental","pubTime":"2024-08-29 15:40","pubTimestamp":1724917211,"startTime":"0","endTime":"0","summary":"Q32 Bio's Bempikibart and ADX-097 are in Phase 2 trials, targeting autoimmune and inflammatory diseases, with significant potential to address unmet medical needs.The company's unique approach of loca","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1206720289/image_1206720289.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1206720289/image_1206720289.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4717805-q32-bio-stock-high-risk-high-reward-with-bempikibart-adx-097","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["LU1670710661.SGD","LU1074936037.SGD","LU0061475181.USD","LU0237698245.USD","LU1670710588.SGD","AMGN","BK4153","BMY","IE0002141913.USD","IE00BSNM7G36.USD","TSLP","LU1093756325.SGD","LU2112291526.USD","BK4007","LU0114720955.EUR","LU0985481810.HKD","IE00BJJMRZ35.SGD","LU0321505868.SGD","IE00BJT1NW94.SGD","LU0320765992.SGD","LU1291159041.SGD","BK4566","BK4534","LU0868494617.USD","LU1585245621.USD","BK4532","LU1983299246.USD","LU1571399168.USD","LU0882574055.USD","SG9999001440.SGD","BK4559","LU0225284248.USD","LU2125154935.USD","LU2242652126.USD","LU1057294990.SGD","ADX","LU1261432733.SGD","LU0289739699.SGD","LU2242646821.SGD","LU0058720904.USD","LU1061106388.HKD","LU2360032135.SGD","LU0122379950.USD","BK4533","LU0225771236.USD","LU1989771016.USD","LU0321505439.SGD","QTTB","AA","LU1023059063.AUD"],"gpt_icon":0},{"id":"2462312894","title":"Press Release: Harbour BioMed Announces 2024 Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2462312894","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2462312894?lang=en_us&edition=fundamental","pubTime":"2024-08-28 17:44","pubTimestamp":1724838240,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2024. CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Aug. 28, 2024 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immunology, today announced its interim results for the six months ended June 30, 2024.Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, commented, \"In the first half of 2024, Harbour BioMed remained profitable, demonstrating the Company's remarkable resilience and adaptability in challenging market conditions. Our global operations continue to open new avenues for future growth. Our outstanding performance has validated the feasibility of the Two-Engine strategy, driven by Harbour Therapeutics and Nona Biosciences. We are confident in our ability to enhance value creation and drive sustainable growth by fully unlocking the tremendous potenti","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK1574","BK4555","BK4022","L","03160","BK1583","BK4107","TSLP","BK4232","R","TM","02142","LU0053666078.USD","BK1161","BK4099","BK4585"],"gpt_icon":0},{"id":"2459872906","title":"Press Release: Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2459872906","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459872906?lang=en_us&edition=fundamental","pubTime":"2024-08-13 21:21","pubTimestamp":1723555260,"startTime":"0","endTime":"0","summary":"--  Presented data for tibulizumab at EULAR 2024, highlighting the. potential relevance of dual-inhibition of both IL-17A and BAFF in. --  Expect to initiate Phase 2 studies evaluating tibulizumab for the. treatment of systemic sclerosis  in 4Q 2024 and hidradenitis. --  Strengthened management and advisory team with appointment of Robert. Lisicki as CEO & formation of Scientific Advisory Board. 2024, including $112.5 million from private placement executed in April. 2024, anticipated to support operations as currently planned through. Zura Bio Limited  , a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported its second quarter 2024 financial results, and recent business highlights.increased serum levels of total IL-17A and BAFF following. rheumatoid arthritis model demonstrate a reduction in inflammation. through the combined inhibition of IL-17A and BAFF, compared to","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","TSLP","BK4139","AA","BK4181","BK4585","ZURA","BK4153","BK4218","INN"],"gpt_icon":0},{"id":"2458086326","title":"Press Release: Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2458086326","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2458086326?lang=en_us&edition=fundamental","pubTime":"2024-08-12 18:30","pubTimestamp":1723458600,"startTime":"0","endTime":"0","summary":"Continued advancement of pipeline and execution towards expected milestones, including APG777 16-week proof-of-concept data from the Phase 2 Part A trial in 2H 2025, APG808 interim Phase 1 data in 4Q 2024, and APG990 Phase 1 trial initiation in healthy volunteers accelerated to 3Q 2024. APG333, a novel subcutaneous half-life extended anti-TSLP antibody, added to portfolio to provide for potential best-in-class combination efficacy across multiple respiratory indications, expected to enter the clinic in 2025. Apogee plans combination studies of 777 + 990  and 777 + 333 , with the potential for greater efficacy across I&I diseases, starting with the first clinical trial of the APG777 and APG990 combination in 2025. $790 million cash, cash equivalents and marketable securities with runway into 2028. in 2H 2025: APG777 is a novel, subcutaneous  extended half-life","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B19Z3581.USD","IE00BHPRN162.USD","IE00B7SZLL34.SGD","LU1861558580.USD","BK4581","APGE","TSLP","BK4551","BK4503","BK4139","BK4227","IE00B19Z3B42.SGD","LU1861559042.SGD","BK4554","LU2065732104.USD","IE0002270589.USD","BK4528","BK4097","BK4106","BK4588","PRGS"],"gpt_icon":0},{"id":"2457974883","title":"AMGEN REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2457974883","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2457974883?lang=en_us&edition=fundamental","pubTime":"2024-08-07 04:01","pubTimestamp":1722974460,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., Aug. 6, 2024 /PRNewswire/ -- Amgen  today announced financial results for the second quarter 2024.\"With a strong, balanced portfolio of in-market products and a rapidly advancing pipeline of innovative medicines, we are confident in our ability to deliver attractive long-term growth,\" said Robert A. Bradway, chairman and chief executive officer.For the second quarter, total revenues increased 20% to $8.4 billion in comparison to the second quarter of 2023.Product sales grew 20%, driven by 26% volume growth, partially offset by 3% lower net selling price. Excluding sales from our Horizon Therapeutics  acquisition, product sales grew 5%, driven by volume growth of 10%.Twelve products delivered at least double-digit sales growth in the second quarter, including Prolia , EVENITY , Repatha , TEZSPIRE , BLINCYTO , and TAVNEOS .Non-GAAP EPS decreased 1% from $5.00 to $4.97, driven by higher operating expenses, including incremental expenses from Horizon, and interest ex","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MUwJUMkfdcxSbG3aWkeckA--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2c1a06bdf6720fdfc4a33394e07a9a88","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MUwJUMkfdcxSbG3aWkeckA--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2c1a06bdf6720fdfc4a33394e07a9a88"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-reports-second-quarter-2024-200100112.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-reports-second-quarter-2024-200100112.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","CRC","LU2242646821.SGD","BK4160","BK4566","BSA","LU1571399168.USD","BK4533","IE0002141913.USD","BK4585","BK4218","BK4534","IE0009355771.USD","LU0122379950.USD","LU2112291526.USD","IE00BJJMRZ35.SGD","MTA","LU0320765992.SGD","GIPR","MPA","LU2242652126.USD","BK4188","IE00B2B36J28.USD","IE00B4R5TH58.HKD","PK","LU1023059063.AUD","BK4213","FCF","SG9999001440.SGD","LU0889565916.HKD","LU0058720904.USD","LU0109394709.USD","LU1061106388.HKD","IE00BFTCPJ56.SGD","BK4588","LU0289739699.SGD","BK4581","LU0868494617.USD","IE00BJT1NW94.SGD","BK4211","TSLP","LU1057294990.SGD","AMGN","BK4181"],"gpt_icon":0},{"id":"2436176128","title":"Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma","url":"https://stock-news.laohu8.com/highlight/detail?id=2436176128","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2436176128?lang=en_us&edition=fundamental","pubTime":"2024-05-20 18:00","pubTimestamp":1716199200,"startTime":"0","endTime":"0","summary":"- ARO-RAGE reduced serum sRAGE by up to 88% in patients with asthma. - Additional promising results presented on two preclinical stage programs targeting thymic stromal lymphopoietin  and influenza A viruses. \"These results underscore the potential of our proprietary TRiMTM platform to enable us to develop impactful new therapies to potentially treat multiple pulmonary diseases with significant unmet needs. Arrowhead was the first company to show that RNAi could be harnessed to achieve high levels of target gene knockdown in the lung in healthy human subjects and these data presented at ATS 2024 build on that success,\" said James Hamilton, M.D., chief of discovery and translational medicine at Arrowhead. \"Our ARO-RAGE data is first-in-class and demonstrated deep and sustained knockdown in the lung in patients with mild to moderate asthma, a long duration of effect that appears to support every two-month dosing, and a favorable safety and tolerability profile. These results give us furt","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/z_Vb7iAWotkZrQ7yEFXUkg--~B/aD0zMzU7dz0xNjA5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/169571ac42077918beba38ae7474aa69","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/z_Vb7iAWotkZrQ7yEFXUkg--~B/aD0zMzU7dz0xNjA5O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/169571ac42077918beba38ae7474aa69"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arrowhead-pharmaceuticals-presents-clinical-data-100000003.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4161","ATS","BK4585","BK4139","BK4588","TSLP","ARWR"],"gpt_icon":0},{"id":"2436719258","title":"NEW DATA PRESENTED AT ATS 2024 SHOW THE POTENTIAL OF TEZSPIRE® TO HELP PATIENTS LIVING WITH COPD","url":"https://stock-news.laohu8.com/highlight/detail?id=2436719258","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2436719258?lang=en_us&edition=fundamental","pubTime":"2024-05-20 05:15","pubTimestamp":1716153300,"startTime":"0","endTime":"0","summary":"Late-Breaking Results From the Phase 2a COURSE Trial Illustrate Tezspire's Impact on COPD Exacerbations in Patients With a Broad Range of Eosinophil Levels. Importantly, this proof-of-concept study showed that, in patients with BEC ≥150 cells/L, tezepelumab led to a nominally significant reduction of 37% in the rate of moderate or severe exacerbations compared to placebo. Studies suggest that approximately 65% of bio-eligible patients with COPD have a BEC ≥150 cells/μL. Among patients with BEC ≥300 cells/L, tezepelumab led to a numerical reduction of 46% in the rate of moderate or severe exacerbations . Trends towards improved outcomes were also seen with tezepelumab use for pre-bronchodilator FEV1 and SGRQ total score.\"I believe biologics will play a critical role in the future care of COPD, and trials such as the tezepelumab COURSE trial are central to understanding and shaping the treatment landscape,\" said Dr. Dave Singh, professor of respiratory pharmacology at the University of M","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MUwJUMkfdcxSbG3aWkeckA--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2c1a06bdf6720fdfc4a33394e07a9a88","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MUwJUMkfdcxSbG3aWkeckA--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2c1a06bdf6720fdfc4a33394e07a9a88"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/data-presented-ats-2024-show-211500623.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/data-presented-ats-2024-show-211500623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0122379950.USD","LU0289739699.SGD","IE00BFTCPJ56.SGD","LU1571399168.USD","LU1057294990.SGD","IE0009355771.USD","IE00BJT1NW94.SGD","LU0109394709.USD","IE00B2B36J28.USD","LU0320765992.SGD","LU2242652126.USD","SG9999001440.SGD","ATS","AMGN","BK4534","IE00BJJMRZ35.SGD","LU0058720904.USD","BK4139","LU0868494617.USD","BK4533","BK4566","LU2242646821.SGD","LU0889565916.HKD","LU1023059063.AUD","BK4161","BK4585","IE0002141913.USD","TSLP","BK4581","BK4588"],"gpt_icon":0},{"id":"2435676034","title":"Johnson & Johnson: Proteologix's Portfolio Includes PX128, a Bispecific Antibody Targeting IL-13 Plus TSLP >JNJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2435676034","media":"DowjonesLive","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2435676034?lang=en_us&edition=fundamental","pubTime":"2024-05-16 19:31","pubTimestamp":1715859060,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"dowjones_live","symbols":["LU1196500208.SGD","IE00B19Z3581.USD","LU1032466523.USD","LU1066053197.SGD","LU1066051498.USD","BK4532","LU0889566641.SGD","IE00B7SZLL34.SGD","BK4585","JNJ","LU1244550577.SGD","BK4534","IE00B1BXHZ80.USD","LU1935042991.SGD","LU0466842654.USD","LU0122379950.USD","LU0912757837.SGD","LU1585245621.USD","LU1732799900.SGD","LU1244550221.USD","LU0792757196.USD","LU1221951129.SGD","LU0114720955.EUR","LU1244550494.USD","LU1430594728.SGD","IE00B19Z3B42.SGD","BK4533","IE0002270589.USD","LU1059921491.USD","LU2347655156.SGD","SG9999002224.SGD","LU0640476718.USD","LU1267930813.SGD","LU1506573853.SGD","LU1221951046.USD","SG9999002232.USD","LU0795875169.SGD","BK4550","LU2468319806.SGD","LU1023059063.AUD","LU1732800096.USD","BK4568","LU1261432733.SGD","TSLP","LU0882574055.USD","LU2602419157.SGD","LU2133065610.SGD","LU1280957306.USD","BK4588","LU1057294990.SGD"],"gpt_icon":0},{"id":"2432953058","title":"AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2432953058","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2432953058?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:01","pubTimestamp":1714680060,"startTime":"0","endTime":"0","summary":"THOUSAND OAKS, Calif., May 2, 2024 /PRNewswire/ -- Amgen  today announced financial results for the first quarter 2024.\"With many of our innovative products delivering strong growth and promising new medicines advancing through our pipeline, we are excited about delivering attractive long-term growth,\" said Robert A.Bradway, chairman and chief executive officer.For the first quarter, total revenues increased 22% to $7.4 billion in comparison to the first quarter of 2023. Product sales grew 22%, driven by 25% volume growth.Ten products delivered at least double-digit volume growth in the first quarter, includingRepatha , TEZSPIRE , EVENITY , BLINCYTO , and TAVNEOS .U.S. volume grew 29% and ex-U.S. volume grew 17%.GAAP loss per share was $0.21 for the first quarter of 2024 compared with GAAP earnings per share  of $5.28 for the first quarter of 2023, driven by a mark-to-market loss on our BeiGene, Ltd. equity investment and higher operating expenses, including higher amortization expense","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/MUwJUMkfdcxSbG3aWkeckA--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2c1a06bdf6720fdfc4a33394e07a9a88","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/MUwJUMkfdcxSbG3aWkeckA--~B/aD05ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/2c1a06bdf6720fdfc4a33394e07a9a88"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2024-200100451.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-reports-first-quarter-2024-200100451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4181","PK","BK4533","BK4211","LU0058720904.USD","BK4534","LU0289739699.SGD","BK4213","BK4161","BK4588","FCF","BK4585","ATS","BK4218","BK4581","TSLP","SG9999001440.SGD","LU0320765992.SGD","LU1023059063.AUD","LU0109394709.USD","AMGN","LU2242652126.USD","BK4566","BK4188","LU1571399168.USD","LU2242646821.SGD","CRC","BK4160","LU0889565916.HKD","GIPR","LU0122379950.USD","MTA","LU0868494617.USD","BK4139","LU1057294990.SGD"],"gpt_icon":0},{"id":"2432652209","title":"AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2432652209","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2432652209?lang=en_us&edition=fundamental","pubTime":"2024-05-01 19:05","pubTimestamp":1714561500,"startTime":"0","endTime":"0","summary":"New data for TEZSPIRE and BREZTRI demonstrate AstraZeneca’s innovation and commitment to transform care in COPD. Sharon Barr, Ph.D., Executive Vice President, BioPharmaceuticals R&D, AstraZeneca said: \"Data at ATS demonstrate our progress in advancing a new wave of innovative treatments, moving beyond symptom control into disease modification, remission and one day, cure. Today, COPD patients have highly limited options if their disease is uncontrolled on inhaled medicines. We’re encouraged by the results of the COURSE Phase IIa data exploring tezepelumab in a broad population of COPD patients beyond those with baseline blood eosinophils above 300 cells/μL and look forward to these data being presented at the ATS International Conference.\". Ruud Dobber, Ph.D, Executive Vice President and President, BioPharmaceuticals Business Unit, AstraZeneca, said: \"Our broad pipeline and portfolio of inhaled and biologic medicines are the cornerstone of our bold ambition to transform respiratory car","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SFraILVy.iBDP9Q3n17LDA--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/4de04cc39f934db71244afaf391c0fbd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SFraILVy.iBDP9Q3n17LDA--~B/aD00NzU7dz0xNDM4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/4de04cc39f934db71244afaf391c0fbd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/astrazeneca-unveils-latest-research-across-110500244.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AZN","CDC","GOLD","LU2236285917.USD","LU0300736062.USD","LU0266512127.USD","LU1223082196.USD","LU1223083913.SGD","LU1169589451.USD","FRI","LU1829250122.USD","IE00B7SZLL34.SGD","BK4213","BK4161","BK4588","LU0498741890.SGD","LU0368265418.SGD","BK4110","BK4585","BK4570","IE00B19Z3B42.SGD","ATS","IE0002270589.USD","SG9999001143.SGD","BK4568","LU0456854461.SGD","TSLP","LU1169590202.USD","LU0320765992.SGD","IE00B19Z3581.USD","LU0075056555.USD","LU1023059493.AUD","LU0109394709.USD","LU0368265764.SGD","LU0122376428.USD","BK4007","BK4532","LU0330918003.SGD","LU0496367417.USD","LU0300736492.USD","LU0055631609.USD","BK4017","LU0498741114.HKD","LU0889565916.HKD","HES","MITT"],"gpt_icon":0},{"id":"2432738795","title":"AMGEN HIGHLIGHTS NEW COPD, ASTHMA AND VASCULITIS RESEARCH AT ATS 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2432738795","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2432738795?lang=en_us&edition=fundamental","pubTime":"2024-05-01 19:00","pubTimestamp":1714561200,"startTime":"0","endTime":"0","summary":"Findings From Tezspire  Phase 2a COURSE COPD Study. Phase 1 Study on AMG104/AZD8630  in Moderate to Severe Asthma. New TAVNEOS  Data in Adults With Severe Active ANCA-Associated Vasculitis With Lung Involvement. THOUSAND OAKS, Calif., May 1, 2024 /PRNewswire/ -- Amgen  today announced the presentation of new respiratory data at the American Thoracic Society 2024 International Conference taking place May 12-22 in San Diego. Thirteen abstracts supporting two approved medicines and one investigational treatment will be presented.\"We look forward to presenting encouraging data from our Phase 2a COURSE trial in COPD with Tezspire and our Phase 1 investigational study of asthma with AMG104/AZD8630, an inhaled anti-TSLP therapy,\" said Jay Bradner, M.D., executive vice president of Research and Development and chief scientific officer at Amgen. \"Our efforts underscore Amgen's commitment to pioneering new treatments for respiratory diseases with currently limited treatment options.\". Other rese","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/fXOCbBYEhALvuJbXuwlWEQ--~B/aD0yMjU7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a085ee332e8e3e11ca5c7e5584018b12"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/amgen-highlights-copd-asthma-vasculitis-110000272.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/amgen-highlights-copd-asthma-vasculitis-110000272.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","ATS","LU2242646821.SGD","BK4566","LU1571399168.USD","LU2242652126.USD","BK4533","LU0122379950.USD","BK4585","BK4534","LU0320765992.SGD","BK4161","LU1023059063.AUD","SG9999001440.SGD","LU0889565916.HKD","LU0058720904.USD","LU0109394709.USD","LU0289739699.SGD","BK4588","BK4581","LU0868494617.USD","TSLP","LU1057294990.SGD","AMGN"],"gpt_icon":0},{"id":"2424003521","title":"What Are YieldMax ETFs: Returns, Peer Comparison & More","url":"https://stock-news.laohu8.com/highlight/detail?id=2424003521","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2424003521?lang=en_us&edition=fundamental","pubTime":"2024-04-03 04:34","pubTimestamp":1712090062,"startTime":"0","endTime":"0","summary":"Yieldmax ETFs have been in the headlines after giving staggering returns to investors. But how good are they when compared to their head on competitor. An ETF is a marketable security that tr","market":"us","thumbnail":"https://academy-public.coinmarketcap.com/srd-optimized-uploads/64b5a7c5be6b4b71813f957782785d3a.webp","type":0,"news_type":0,"thumbnails":["https://academy-public.coinmarketcap.com/srd-optimized-uploads/64b5a7c5be6b4b71813f957782785d3a.webp"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/660c6bd07419ca3b2e90013f/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["NFLX","LU0316494557.USD","LU1435385759.SGD","LU1989764664.SGD","IE00BJJMRX11.SGD","LU0211327993.USD","IE00BBT3K403.USD","LU0310799852.SGD","LU1914381329.SGD","IE00BFSS8Q28.SGD","MSFT","IE00B1XK9C88.USD","IE00B1BXHZ80.USD","LU1571399168.USD","LU0354030511.USD","LU0109391861.USD","LU0289960550.SGD","LU2249611893.SGD","IE00BLSP4239.USD","FDN","IE00B3S45H60.SGD","LU0354030438.USD","IE00B7KXQ091.USD","LU0353189680.USD","LU1429558221.USD","LU1551013425.SGD","LU0061474705.USD","LU1551013342.USD","LU0251142724.SGD","TSLA","IE00B19Z9505.USD","LU1691799644.USD","TSLP","LU0061474960.USD","LU0823414478.USD","LU0130102774.USD","LU0353189763.USD","IE00BJTD4N35.SGD","LU0079474960.USD","LU0889565833.HKD","SGXZ23171101.USD","GPRO","LU1804176565.USD","GOOG","LU1823568750.SGD","LU1280957306.USD","NAV","GOOGL","LU0130103400.USD"],"gpt_icon":0},{"id":"2422722157","title":"Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2422722157","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2422722157?lang=en_us&edition=fundamental","pubTime":"2024-03-28 18:00","pubTimestamp":1711620000,"startTime":"0","endTime":"0","summary":"Significant 2023 milestones highlighted by successful Nasdaq listing, leadership team buildout, formation of strategic development and scientific plan. On track to initiate Phase 2 study evaluating tibulizumab  for the treatment of systemic sclerosis  in 2H 2024. Outgoing Founder and CEO, Someit Sidhu, M.D., will continue as a Board Director to leverage institutional knowledge and provide continued support. Cash position as of December 31, 2023 totaling $99.8 million in cash, cash equivalents, and investments expected to support development and operations into 2026. Dr. Sidhu continued, \"On behalf of the Management Team and Board, I am pleased to welcome Robert as the Chief Executive Officer. Robert brings a wealth of industry leadership experience complemented by expertise in drug development and commercial operations. With his proven track record of excellence, he is the right individual to lead Zura Bio as our lead asset enters Ph","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_WycdGfaFQsHKigALo.GXA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2bc19fc79c3f1bd7c7adf5d8ada6fe35","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_WycdGfaFQsHKigALo.GXA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/2bc19fc79c3f1bd7c7adf5d8ada6fe35"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/zura-bio-reports-full-2023-100000175.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ZURAW","CEO","ZURA","BK4139","TSLP"],"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":0.0285},{"period":"1month","weight":0.039},{"period":"3month","weight":0.1636},{"period":"6month","weight":0.2339},{"period":"1year","weight":-0.048},{"period":"ytd","weight":-0.1599}],"compareEarnings":[{"period":"1week","weight":0.0111},{"period":"1month","weight":0.0136},{"period":"3month","weight":0.0436},{"period":"6month","weight":0.0903},{"period":"1year","weight":0.3173},{"period":"ytd","weight":0.1955}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"The fund is an actively managed exchange traded fund that seeks current income while maintaining the opportunity for exposure to the share price (i.e., the price returns) of the common stock of Tesla Inc. (“TSLA”); however the strategy limits potential investment gains related to share price appreciation. The fund seeks to employ its investment strategy as it relates to TSLA in all market, economic, or other conditions. The fund is non-diversified.","exchange":"AMEX","name":"Kurv Yield Premium Strategy Tesla (TSLA) ETF","nameEN":"Kurv Yield Premium Strategy Tesla (TSLA) ETF"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kurv Yield Premium Strategy Tesla (TSLA) ETF(TSLP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kurv Yield Premium Strategy Tesla (TSLA) ETF(TSLP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kurv Yield Premium Strategy Tesla (TSLA) ETF,TSLP,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票老虎,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票老虎国际,Kurv Yield Premium Strategy Tesla (TSLA) ETF行情,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票行情,Kurv Yield Premium Strategy Tesla (TSLA) ETF股价,Kurv Yield Premium Strategy Tesla (TSLA) ETF股市,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票价格,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票交易,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票购买,Kurv Yield Premium Strategy Tesla (TSLA) ETF股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kurv Yield Premium Strategy Tesla (TSLA) ETF(TSLP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kurv Yield Premium Strategy Tesla (TSLA) ETF(TSLP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction